Albin Jeanne

Dr. Albin JEANNE is the CEO of Apmonia Therapeutics (Reims, France). He combines strong strategic, technological, and managerial skills with over 10-year experience in translational drug development. Albin JEANNE co-founded Apmonia Therapeutics in 2019 and has raised as of now a total of more than €10 million from VCs and strategic partners in Europe. As a co-inventor of TAX2 patents, he engineered the first ever antagonists being selective for TSP- 1/CD47 interaction, has authored 15 peer-reviewed scientific publications on extracellular matrix pathobiology, and won numerous international awards.

Albin JEANNE holds a PhD in biochemistry & cell biology and completed the Challenge+ program at HEC international business school.